Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
about
Targeted approaches to induce immune tolerance for Pompe disease therapyDurable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responsesAlgorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapyClinical Laboratory Experience of Blood CRIM Testing in Infantile Pompe DiseaseSuccessful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy.Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease.High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.c.1437G>A intron 9 substitution on acid α-glucosidase gene associated with classic infantile-onset Pompe disease phenotype.CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy.Current and Future Treatments for Lysosomal Storage Disorders.Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients.Enzyme replacement therapy in India: Lessons and insights
P2860
Q26767363-3500A121-06EC-4605-9B5E-36C535876389Q28595509-EE0CAC88-1506-4E6E-9103-B7A71D210E8BQ34794660-BD62572D-E2F4-4533-8B46-5D377075E83BQ35123163-ABC302D0-A0E7-4BA5-B8A0-0E538E4235D7Q36030998-212C299A-6965-428E-83AE-AFA637E1C3F4Q36361194-65DC1BF4-2B90-455B-8EFB-142748CEDBE6Q37500689-5117D87F-CB95-40CE-8203-5215E7D63AD6Q37694653-2C021AE1-EC27-44A5-ADC8-EE7497E2331FQ38615407-E5B50B7E-8197-420B-9D31-CA713F850B81Q38621461-239126E2-D531-465B-B3ED-0EEE3CB21DA6Q38675468-3E5F855B-13DA-4FCD-923B-78DCB8A912A3Q40158700-88415A02-56EF-447A-99FA-3F2210FB5E4DQ41110732-82847C6A-CC8D-42BA-BD1D-99203E4B382CQ42183681-837386E7-A43F-41C1-AAFC-BBACE8A83805Q45873942-F63EAB8C-3D9B-420B-8CCD-8DC7B316FBB7Q47670496-0BA92A5E-A2FD-42CA-B500-C28287F1FAE2Q49419700-8F35A333-95B5-4DA8-8EFD-798A6F7AB891Q55709382-AF59D8BD-2FD9-4DD7-9289-E76BB0A7CCA6Q58790995-2263D0A8-11A9-44F7-9D50-3D002D691D80
P2860
Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Predicting cross-reactive immu ...... laboratory testing experience.
@ast
Predicting cross-reactive immu ...... laboratory testing experience.
@en
type
label
Predicting cross-reactive immu ...... laboratory testing experience.
@ast
Predicting cross-reactive immu ...... laboratory testing experience.
@en
prefLabel
Predicting cross-reactive immu ...... laboratory testing experience.
@ast
Predicting cross-reactive immu ...... laboratory testing experience.
@en
P2093
P2860
P356
P1476
Predicting cross-reactive immu ...... laboratory testing experience.
@en
P2093
Catherine Rehder
Deeksha S Bali
Jennifer L Goldstein
Joanne Mackey
Priya S Kishnani
Suhrad Banugaria
P2860
P356
10.1002/AJMG.C.31319
P577
2012-01-17T00:00:00Z